Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


13.08.2018

1 Am J Dermatopathol
2 Am J Ophthalmol
1 Cancer Res
1 Clin Cancer Res
1 Int J Cancer
4 J Am Acad Dermatol
1 J Biol Chem
1 J Invest Dermatol
3 Melanoma Res
2 N Engl J Med


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Dermatopathol

  1. TRAN TAN, Linos K, de Abreu FB, Carlson JA, et al
    Undifferentiated Sarcoma as Intermediate Step in the Progression of Malignant Melanoma to Rhabdomyosarcoma: Histologic, Immunohistochemical, and Molecular Studies of a New Case of Malignant Melanoma With Rhabdomyosarcomatous Differentiation.
    Am J Dermatopathol. 2018 Aug 6. doi: 10.1097/DAD.0000000000001236.
    PubMed     Text format     Abstract available


    Am J Ophthalmol

  2. CAI L, Paez-Escamilla M, Walter SD, Tarlan B, et al
    Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.
    Am J Ophthalmol. 2018 Aug 6. pii: S0002-9394(18)30438.
    PubMed     Text format     Abstract available

  3. DEMIRCI H, Niziol LM, Ozkurt Z, Slimani N, et al
    Do Largest Basal Tumor Diameter and the American Joint Commission Cancer Staging Influence Prognostication by Gene Expression Profiling in Choroidal Melanoma?
    Am J Ophthalmol. 2018 Aug 3. pii: S0002-9394(18)30426.
    PubMed     Text format     Abstract available


    Cancer Res

  4. HUANG M, Qi TF, Li L, Zhang G, et al
    A targeted quantitative proteomic approach assesses the reprogramming of small GTPases during melanoma metastasis.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-17-3811.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  5. GOTTESDIENER LS, O'Connor S, Busam KJ, Won H, et al
    Rates of ERBB2 Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-amplified Acral Melanoma.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-1397.
    PubMed     Text format     Abstract available


    Int J Cancer

  6. ANDRES-LENCINA JJ, Rachakonda S, Garcia-Casado Z, Srinivas N, et al
    TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31780.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  7. BREGEON B, Bernier C, Josselin N, Peuvrel L, et al
    DRESS syndrome induced by the combination of vemurafenib and cobimetinib in melanoma: a series of 11 cases.
    J Am Acad Dermatol. 2018 Aug 3. pii: S0190-9622(18)32329.
    PubMed     Text format    

  8. SALVIO AG, Inada NM, Bagnato VS, Kurachi C, et al
    The use of LED imaging as exclusion criterion for melanoma diagnosis.
    J Am Acad Dermatol. 2018 Aug 3. pii: S0190-9622(18)32331.
    PubMed     Text format    

  9. GASTMAN BR, Gerami P, Kurley SJ, Cook RW, et al
    Identification of patients at risk for metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
    J Am Acad Dermatol. 2018 Aug 3. pii: S0190-9622(18)32328.
    PubMed     Text format     Abstract available

  10. GHAZAWI FM, Cyr J, Darwich R, Le M, et al
    Cutaneous Malignant Melanoma Incidence and Mortality Trends in Canada: A Comprehensive Population-based Study.
    J Am Acad Dermatol. 2018 Aug 6. pii: S0190-9622(18)32343.
    PubMed     Text format     Abstract available


    J Biol Chem

  11. WU Q, Fung AHY, Xu ML, Poon K, et al
    Microphthalmia-associated transcription factor up-regulates acetylcholinesterase expression during melanogenesis of murine melanoma cells.
    J Biol Chem. 2018 Aug 3. pii: RA118.003729. doi: 10.1074/jbc.RA118.003729.
    PubMed     Text format     Abstract available


    J Invest Dermatol

  12. SAHOO A, Sahoo SK, Joshi P, Lee B, et al
    MicroRNA-211 loss promotes metabolic vulnerability and BRAF inhibitor sensitivity in melanoma.
    J Invest Dermatol. 2018 Aug 1. pii: S0022-202X(18)32458.
    PubMed     Text format     Abstract available


    Melanoma Res

  13. YAN J, Wu X, Yu J, Ma M, et al
    Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics.
    Melanoma Res. 2018 Aug 6. doi: 10.1097/CMR.0000000000000494.
    PubMed     Text format     Abstract available

  14. GROGAN N, Swami U, Bossler AD, Zakharia Y, et al
    Toxicities with targeted therapies after immunotherapy in metastatic melanoma.
    Melanoma Res. 2018 Aug 6. doi: 10.1097/CMR.0000000000000493.
    PubMed     Text format     Abstract available

  15. LIU G, Wang Y, Fei F, Wang X, et al
    Clinical characteristics and preliminary morphological observation of 47 cases of primary anorectal malignant melanomas.
    Melanoma Res. 2018 Aug 3. doi: 10.1097/CMR.0000000000000491.
    PubMed     Text format     Abstract available


    N Engl J Med

  16. BARKER CA
    Adjuvant Pembrolizumab in Resected Stage III Melanoma.
    N Engl J Med. 2018;379:593.
    PubMed     Text format    


  17. Adjuvant Pembrolizumab in Resected Stage III Melanoma.
    N Engl J Med. 2018;379:593-595.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: